Should We Treat SIBO Patients? Impact on Quality of Life and Response to Comprehensive Treatment: A Real-World Clinical Practice Study
Nutrients · 2025
DOI: 10.3390/nu17071251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Ana Reyes Liébana-Castillo und 24 weiteren Autor:innen. Beteiligte Einrichtung: Valencian Digestive Institute (IVADI), 46021 Valencia, Spain. Hauptthemen laut MEDLINE: Quality of Life, Blind Loop Syndrome, Intestine, Small. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Small intestinal bacterial overgrowth (SIBO) is a dysbiosis marked by an excessive proliferation of bacteria in the small intestine, resulting in abdominal symptoms that significantly affect patients’ quality of life.
Objectives
This study aims to evaluate the impact of a comprehensive therapeutic approach in improving the quality of life of patients with SIBO.
Methods
For this purpose, standardized questionnaires were used at baseline, 30 days and 90 days, including the IBS-QOL (Irritable Bowel Syndrome Quality of Life Questionnaire), the GSRS (Gastrointestinal Symptom Rating Scale), the EuroQOL-5D, and the Bristol Scale.
Results
The results show that a comprehensive approach, combining pharmacological treatment, appropriate dietary intervention, and strategies aimed at improving gut microbiota and intestinal permeability, produces a sustained improvement in the quality of life of a significant proportion of patients who participated in the study. Furthermore, the results suggest that, although gas normalization is a relevant indicator, clinical improvement and quality of life depend considerably on patients’ subjective perception of their health.
Conclusions
This finding underscores the importance of recognizing SIBO as a prevalent condition that requires accurate diagnoses and individualized treatments to improve patients’ well-being.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Valencian Digestive Institute (IVADI), 46021 Valencia, Spain.
- Digestive Section, Hospital de Sagunto Internal Medicine Service, 46520 Valencia, Spain.
- Department of Pharmacology, Pediatrics and Organic Chemistry, Miguel Hernández University of Elche, 03550 Elche, Spain.
ORCID-Profile: Lucía Redondo-Cuevas, Vanessa Martín-Carbonell, Laura Sanchis, María Leonor Molina, Ernesto Cortés-Castell, Xavier Cortés-Rizo
Zitieren
APA
Liébana-Castillo, A. R., Redondo-Cuevas, L., Nicolás, Á., Martín-Carbonell, V., Sanchis, L., Olivares, A., Grau, F., Ynfante, M., Colmenares, M., Molina, M. L., Lorente, J. R., Tomás, H., Moreno, N., Garayoa, A., Jaén, M., Mora, M., Gonzalvo, J., Molés, J. R., Díaz, S., …, & Cortés-Rizo, X. (2025). Should We Treat SIBO Patients? Impact on Quality of Life and Response to Comprehensive Treatment: A Real-World Clinical Practice Study. Nutrients. https://doi.org/10.3390/nu17071251
Vancouver
Liébana-Castillo AR, Redondo-Cuevas L, Nicolás Á, Martín-Carbonell V, Sanchis L, Olivares A, et al. Should We Treat SIBO Patients? Impact on Quality of Life and Response to Comprehensive Treatment: A Real-World Clinical Practice Study. Nutrients. 2025. doi:10.3390/nu17071251
BibTeX
@article{LibanaCastillo2025,
author = {Liébana-Castillo, Ana Reyes and Redondo-Cuevas, Lucía and Nicolás, Ángela and Martín-Carbonell, Vanessa and Sanchis, Laura and Olivares, Aroa and Grau, Francisco and Ynfante, Marina and Colmenares, Michel and Molina, María Leonor and Lorente, José Ramón and Tomás, Héctor and Moreno, Nadia and Garayoa, Ana and Jaén, Mercedes and Mora, María and Gonzalvo, José and Molés, José Ramón and Díaz, Samuel and Sancho, Noelia and Sánchez, Eva and Ortiz, Juan and Gil-Guillén, Vicente and Cortés-Castell, Ernesto and Cortés-Rizo, Xavier},
title = {Should We Treat SIBO Patients? Impact on Quality of Life and Response to Comprehensive Treatment: A Real-World Clinical Practice Study},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17071251}
}
EUVIMED